Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Bevacizumab or EGFR antibodies

Earn CME for related activities: www.naccme.com/oln
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that either bevacizumab or EGFR antibodies are the preferred targeted therapy for RAS/BRAF wild-type left sided colon cancers.

[@drsachinborse]

Nice info....

[@senatorsantor9556]

İs there any new improvements (drugs) for kras,nras,braf v600d mut. To get over? Thank you

[@ahmedahm1]

1:40